Phase 1 Stomach Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have a type of tumour called a gastroenteropancreatic neuroendocrine tumour (NET) that has spread only to the lymph nodes or liver
- People whose tumour is classified as a slow-growing type (WHO Grade 1 or 2, with a cell growth rate of 20% or less), which will be confirmed at Stanford
- People whose medical team has agreed, after a group review, that surgery to remove as much of the tumour as possible is a suitable option
- People whose tumour can be measured using standard imaging guidelines (called RECIST v1.1)
- People whose tumour shows the presence of a specific protein called somatostatin receptors on all target areas, confirmed by a special type of scan (68Ga DOTATATE PET scan)
- People aged 18 or older
- People who are generally well enough to carry out light activity and care for themselves (a standard measure of physical fitness used in cancer trials)
- People with adequate blood, liver, and kidney function
- People who have been taking a medication called octreotide LAR (at a dose of 20 mg or 30 mg every 3 to 4 weeks) for at least 12 weeks before joining the trial
Who may not be able to join:
- People who have previously been treated with a medication called 177Lu Dotatate (also known as Lutathera)
- People who have had surgery or a procedure called radiofrequency ablation within the 12 weeks before joining; or who have ever had radioembolization, chemoembolization, or radiation therapy covering more than 25% of the bone marrow
- People who have received chemotherapy or targeted therapy drugs (including everolimus or sunitinib) within 4 weeks before joining
- People whose cancer has spread to the brain
- People whose cancer has spread to the bones or the lining of the abdomen (peritoneum)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Brendan C Visser, MD, Stanford Universiy
Phone: (650) 498-7757
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Measure Complication free Surgery
Can't join this trial?
Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.